Freeze-thaw cycle comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reconstitution introduces additional variables: solvent choice, pH, ionic strength, and filtration. Many sequences dissolve readily in water, while hydrophobic ones may need acetonitrile, dimethyl sulfoxide, or a small amount of base. Adding solvent slowly and avoiding vigorous vortexing can reduce foaming and shear-induced aggregation. If the solution appears cloudy, filtration may remove particulates but can also remove aggregated peptide and alter concentration. A clear solution does not by itself confirm correct sequence or purity, so analytical checks remain necessary.
Temperature logs and cold-chain documentation help identify excursions that may compromise a batch. Automated freezers, desiccant packs, and sealed containers limit moisture and frost accumulation. Aliquoting small portions before freezing reduces the number of times the main stock changes temperature. Labels should include peptide name, lot, concentration if known, solvent, and date prepared. Periodic analytical verification by high-performance liquid chromatography or mass spectrometry can detect degradation, truncation, or sequence errors that visual inspection cannot reveal.
Practical handling begins with an inventory record that links each vial to a lot number, synthesis date, and purity certificate. Before opening a container, allow it to equilibrate to room temperature to prevent condensation on the powder. Weighing or transferring should occur in a low-humidity environment using tools that minimize static and adsorption. Hygroscopic peptides may gain water quickly, changing mass and concentration estimates. Recording the container's initial mass and any visible changes supports later reconciliation of material.
Receiving a peptide begins with recording its identity, lot number, quantity, and arrival condition. Dry material is often kept in sealed containers with desiccant and an inert headspace to limit moisture and oxygen. Containers should be compatible with the peptide and solvent; some peptides adsorb to certain plastics or glass. Labels should include date, concentration, solvent, and storage location. A centralized inventory with temperature logs helps prevent loss and mix-ups.
Reconstitution involves adding a solvent to dry peptide, often water or a buffered solution. The chosen liquid should match the peptide's solubility and intended assay, and it should be free of contaminants. Gentle mixing or inversion reduces foaming and shear, which can damage some peptides. If the peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help. The final solution is typically clarified before use in analytical or laboratory procedures.
After reconstitution, solutions are usually divided into single-use aliquots to limit repeated handling. Each aliquot is stored at a temperature appropriate for the peptide, with -20 °C or -80 °C common for longer-term laboratory storage. Freeze-thaw cycles are minimized because they can cause aggregation, precipitation, or loss of activity. Temperature monitoring and documented storage conditions support reproducibility across experiments. When a peptide is removed from storage, it is typically allowed to equilibrate before opening to reduce condensation.
| Property | Value | Notes |
|---|---|---|
| Container material | Glass or polypropylene | Glass is relatively inert but can adsorb; polypropylene may leach. |
| Headspace gas | Argon or nitrogen | Inert gas displaces oxygen for oxidation-prone sequences. |
| Equilibration before opening | 20–30 minutes at room temperature | Sealed vial warms gradually to reduce condensation. |
| Typical aliquot size | Small working portions | Limits repeated temperature cycling of the main stock. |
| Documentation fields | Lot, date, solvent, concentration | Supports traceability and degradation monitoring. |
Reconstitution introduces new variables. The solvent should match the peptide's solubility profile, and water or buffer quality matters because trace metals and microbes can alter results. Adding solvent gently down the vial wall minimizes foaming, which can denature some sequences. Mixing by gentle inversion or swirling is usually preferred over vigorous vortexing. If a peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help, but such steps can also affect stability and should be documented.
Quality control links handling to measurable identity and purity. Reverse-phase high-performance liquid chromatography can separate peptide variants and reveal impurities. Mass spectrometry confirms molecular mass and can detect truncations or modifications. These methods are often paired with ultraviolet absorbance or amino acid analysis for concentration. Documentation of instrument settings, column type, and reference standards supports reproducibility. For research materials, acceptance criteria depend on the intended application, and no universal purity threshold applies to all peptides.
Handling begins when a peptide container is opened. Hygroscopic solids can absorb atmospheric water rapidly, so bench work should be brief and containers resealed with fresh desiccant. Weighing or transferring should occur in a low-humidity environment where possible. Static electricity may cause fine powders to cling to surfaces, leading to inaccurate mass measurements. Tools such as antistatic devices or grounded workstations reduce that problem. Good laboratory practice also includes labeling date, lot, and storage condition after each opening.
Receipt and inventory practices begin with inspection of packaging, temperature indicators, and lot-specific documentation. A certificate of analysis typically reports purity, identity, and sometimes residual water or counterion content. Containers should be labeled with the peptide name, lot number, date received, and storage location. Before a sealed vial is opened, it is often equilibrated to room temperature to reduce condensation on the contents. Clean tools, gloves, and a designated workspace limit contamination and accidental adsorption losses.
Aliquoting reduces repeated temperature cycling for solutions and reconstituted samples. If a peptide is supplied as a powder, reconstitution usually involves adding a suitable solvent gently along the vial wall. Mixing by inversion or slow swirling is preferred over vortexing, which can create air-liquid interfaces that promote aggregation or foaming. The resulting solution should be inspected for clarity, particles, and color before storage. Labels on aliquots typically include concentration, solvent, date, and lot number, and open questions remain about the best solvent for every sequence.
Quality control relies on analytical methods that detect changes in purity, identity, and concentration. Reverse-phase high-performance liquid chromatography separates the parent peptide from degradation products, while mass spectrometry confirms molecular mass. Water content can be measured by Karl Fischer titration, and amino acid analysis or peptide mapping may reveal sequence-level modifications. Stability studies compare stored samples against baseline material at defined intervals. Documentation should link each result to a lot number, storage condition, and test date so that trends can be reviewed.
Handling begins before a peptide arrives at the bench. Containers should be inspected for cracks, loose caps, or visible moisture, and labels should record identity, lot, and receipt date. Lyophilized material is often allowed to equilibrate to room temperature before opening to prevent condensation on the powder. Gloves and a clean workspace reduce contamination and static-related loss. Once opened, the vial may be purged with inert gas and resealed if the peptide is sensitive to oxygen or humidity. These steps are procedural safeguards rather than guarantees of stability.
Reconstitution introduces new risks because the peptide contacts solvent, air, and container surfaces. The chosen solvent should match the peptide's solubility profile, and buffer salts, pH, and ionic strength can affect dissolution and subsequent stability. Gentle mixing is preferred over vigorous vortexing, which can create interfaces and shear. If the solution is not clear, the cause may be incomplete dissolution, aggregation, or insoluble counter-ions rather than a simple concentration problem. Filtration is sometimes used, but filters can adsorb peptides and alter measured concentration.
Cold-chain practice relies on documented temperature ranges, calibrated monitoring, and minimized excursions. Shipments may use insulated boxes, phase-change materials, or dry ice, with data loggers to record conditions. Upon receipt, the recipient should verify the logger trace and place items into long-term storage promptly. Repeated warming and cooling during transfers can be more harmful than a single controlled excursion. For solutions, dividing material into single-use aliquots reduces the number of thawing and refreezing events and limits repeated opening of the same container.
John D. Rockefeller Sr. first conceived the idea of the foundation in 1901. In 1906, Rockefeller's business and philanthropic advisor, Frederick Taylor Gates, encouraged him toward "permanent corporate philanthropies for the good of Mankind" so that his heirs should not "dissipate their inheritances or become intoxicated with power." In 1909 Rockefeller signed over 73,000 Standard Oil shares worth $50 million, to his son, Gates and Harold Fowler McCormick as the third inaugural trustee, in the first installment of a projected $100 million endowment. The nascent foundation applied for a federal charter in the US Senate in 1910, with at one stage Junior even secretly meeting with President William Howard Taft, through the aegis of Senator Nelson Aldrich, to hammer out concessions. However, because of the ongoing (1911) antitrust suit against Standard Oil at the time, along with deep suspicion in some quarters of undue Rockefeller influence on the spending of the endowment, the result was that Senior and Gates withdrew the bill from Congress in order to seek a state charter from New York.
== Inhibitors == Many inhibitors of OGT enzymatic activity have been reported. OGT inhibition results in global downregulation of O-GlcNAc. Cells appear to upregulate OGT and downregulate OGA in response to OGT inhibition.
The city of Sibiu, with its Brukenthal National Museum, was selected as the 2007 European Capital of Culture and the 2019 European Region of Gastronomy. Multiple castles exist in Romania, including the popular tourist attractions of Peleș Castle, Corvin Castle, and Bran Castle or "Dracula's Castle".
Sources: en.wikipedia.org
Bodybuilding is the practice of progressive resistance exercise to build, control, and develop one's muscles via hypertrophy. An individual who engages in this activity is referred to as a bodybuilder. It is primarily undertaken for aesthetic purposes over functional ones, distinguishing it from similar activities such as powerlifting and calisthenics. In competitive bodybuilding, competitors appear onstage in line-ups and perform specified poses (and later individual posing routines) for a panel of judges who rank them based on conditioning, muscularity, posing, size, stage presentation, and symmetry. Bodybuilders prepare for competitions by exercising and eliminating non-essential body fat. This is enhanced at the final stage by a combination of carbohydrate loading and dehydration to achieve maximum muscle definition and vascularity. Most bodybuilders also tan and shave their bodies prior to competition.
== Function == Several lines of evidence suggest that PD-1 and its ligands negatively regulate immune responses. PD-1 knockout mice have been shown to develop lupus-like glomerulonephritis and dilated cardiomyopathy on the C57BL/6 and BALB/c backgrounds, respectively. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. IFN-γ is a key pro-inflammatory cytokine that promotes T cell inflammatory activity. Reduced T cell proliferation was also correlated with attenuated IL-2 secretion and together, these data suggest that PD-1 negatively regulates T cell responses. Experiments using PD-L1 transfected DCs and PD-1 expressing transgenic (Tg) CD4+ and CD8+ T cells suggest that CD8+ T cells are more susceptible to inhibition by PD-L1, although this could be dependent on the strength of TCR signaling. Consistent with a role in negatively regulating CD8+ T cell responses, using an LCMV viral vector model of chronic infection, Rafi Ahmed's group showed that the PD-1-PD-L1 interaction inhibits activation, expansion and acquisition of effector functions of virus specific CD8+ T cells, which can be reversed by blocking the PD-1-PD-L1 interaction. Expression of PD-L1 on tumor cells inhibits anti-tumor activity through engagement of PD-1 on effector T cells. Expression of PD-L1 on tumors is correlated with reduced survival in esophageal, pancreatic and other types of cancers, highlighting this pathway as a target for immunotherapy.
They take an intact bone image sample (region of interest, ROI, reference site) and a sample of the implantation site (second ROI, test site) can be assessed numerically/objectively to what extent the implantation site imitates a healthy bone and how advanced is the process of bone regeneration Fast-Versus Slow-Resorbable Calcium Phosphate Bone Substitute Materials—Texture Analysis after 12 Months of Observation New Oral Surgery Materials for Bone Reconstruction—A Comparison of Five Bone Substitute Materials for Dentoalveolar Augmentation. It is also possible to check whether the bone healing process is influenced by some systemic factors Influence of General Mineral Condition on Collagen-Guided Alveolar Crest Augmentation.
Banik, U., Mandal, N.C., Bhattacharyya, B., & Roy, S.* (1993) J Biol Chem, 268, 3938-3943. https://doi.org/10.1016/S0021-9258(18)53562-6 An operator induced conformational change of C-terminal domain of l-repressor. Saha, R., Banik, U., Mandal, N.C., Bhattacharyya, B., & Roy, S.* (1992) J Biol Chem, 267, 5862-5867. https://doi.org/10.1016/S0021-9258(18)42633-6 15N-guanosine-labeled oligonucleotide as probe for protein-nucleic acid interaction in the major groove. Massefski, W., Redfield, AG., Das Sarma, U., Bannerji, A., & Roy, S.* (1990) J Am Chem Soc, 112, 5350-5351. https://doi.org/10.1021/ja00169a052 Solid state deuterium NMR study of thymidine. Base rigidity and ribose ring flexibility in deoxynucleosides. Hiyama, Y., Roy, S., Cohen, JS. & Torchia, DA. (1989) J Am Chem Soc, 111, 8609-8613. https://doi.org/10.1021/ja00205a008 New enzymic synthesis of 2'-deoxynucleoside-2',2'-d2 and the determination of sugar ring flexibility by solid-state deuterium NMR. Roy, S.,* Hiyama, Y., Torchia, DA., & Cohen, JS. (1986) J Am Chem Soc, 108, 1675-1678. https://doi.org/10.1021/ja00267a043 NMR study of slowly exchanging protons in yeast tRNAasp. Figueroa, N., Keith, G., Leroy, J.L., Plateau, P., Roy, S., & Gueron, M. (1983) Proc Natl Acad Sci (USA), 80, 4330-4333. https://doi.org/10.1073/pnas.80.14.4330 Nuclear Overhauser effect study of yeast tRNAvalI:Evidence of uridine-Pseudouridine base pairing. Schejter, E., Roy, S., Sanchez, V., & Redfield, AG. (1982) Nucleic Acids Res, 10, 8297-8305.
Sources: en.wikipedia.org
Pyruvate is plentiful in muscle due to extensive glycolysis. Amino groups in skeletal muscles are transferred to a product of glycolysis, pyruvate, forming alanine. This transamination reaction is catalyzed by alanine aminotransferase. Alanine is then transported to the liver, where it is converted back into pyruvate (used for gluconeogenesis) by transferring its amino group to α-ketoglutarate, forming glutamate. Simultaneously, glucose is being transported from the liver (where it's more abundant due to gluconeogenesis) to the muscle, where it is consumed. This is the glucose-alanine cycle.
=== "Revolution within a Revolution": 1987–1998 === The late 1980s saw a series of liberalizing economic reforms within Libya designed to cope with the decline in oil revenues. In May 1987, Gaddafi announced the start of the "Revolution within a Revolution", which began with reforms to industry and agriculture and saw the re-opening of small business. Restrictions were placed on the activities of the Revolutionary Committees; in March 1988, their role was narrowed by the newly created Ministry for Mass Mobilization and Revolutionary Leadership to restrict their violence and judicial role, while in August 1988 Gaddafi publicly criticized them. In March, hundreds of political prisoners were freed, with Gaddafi falsely claiming that there were no further political prisoners in Libya. In June, Libya's government issued the Great Green Charter on Human Rights in the Era of the Masses, in which 27 articles laid out goals, rights, and guarantees to improve the situation of human rights in Libya, restricting the use of the death penalty and calling for its eventual abolition. Many of the measures suggested in the charter would be implemented the next year, although others remained inactive. Also in 1989, the government founded the Al-Gaddafi International Prize for Human Rights, to be awarded to figures from the Third World who had struggled against colonialism and imperialism; the first year's winner was South African anti-apartheid activist Nelson Mandela.
== Epidemiology == While the exact incidence is unknown, estimates range from 33 - 57 percent of patients staying in the ICU for longer than 7 days. More exact data is difficult to obtain, since variation exists in defining the condition. The three main risk factors for CIP and CIM are sepsis and systemic inflammatory response syndrome (SIRS), and multi-organ failure. Reported rates of CIP/CIM in people with sepsis and SIRS range from 68 to 100 percent. Additional risk factors for developing CIP/CIM include: female gender, high blood sugar (hyperglycemia), low serum albumin, and immobility. A greater severity of illness increases the risk of CIP/CIM. Such risk factors include: multi-organ dysfunction, kidney failure, renal replacement therapy, duration of organ dysfunction, duration of ICU stay, and central neurologic failure. Certain medications are associated with CIP/CIM, such as corticosteroids, neuromuscular blocking agents, vasopressors, catecholamines, and intravenous nutrition (parenteral nutrition). Research has produced inconsistent results for the impact of hypoxia, hypotension, hyperpyrexia, and increased age on the risk of CIP/CIM. The use of aminoglycosides is not an independent risk for the development of CIP/CIM.
Sources: en.wikipedia.org
Work quickly in a dry environment and keep the container closed when not in use. Equilibrate sealed vials to room temperature before opening to reduce condensation. Record mass changes, as absorbed water can affect concentration calculations.
Liquid storage is generally shorter than dry storage because water enables hydrolysis, oxidation, and microbial growth. If solution storage is necessary, use sterile technique, appropriate pH, and cold temperatures. Aliquot to avoid repeated temperature changes.
Reversed-phase high-performance liquid chromatography is common for purity assessment, while mass spectrometry confirms molecular mass and can reveal modifications. Amino acid analysis or sequencing may be used when sequence information is critical. These methods complement visual inspection and storage records.
Dry peptides are generally kept in sealed, desiccated containers at low temperature, often -20 °C or colder. Protection from light, moisture, and oxygen helps slow degradation. The exact condition depends on the peptide sequence and supplier guidance.